{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:46:58Z","timestamp":1793191618649,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eplepsyres.2020.106535","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T05:57:54Z","timestamp":1609394274000},"page":"106535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan"],"prefix":"10.1016","volume":"170","author":[{"given":"Miyuki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2020.106535_bib0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12611","article-title":"Audit of use of stiripentol in adults with Dravet syndrome","volume":"135","author":"Balestrini","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14737175.2019.1593142","article-title":"Stiripentol for the treatment of seizures associated with Dravet syndrome","volume":"19","author":"Chiron","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0015","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3988\/jcn.2018.14.1.22","article-title":"Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations","volume":"14","author":"Cho","year":"2018","journal-title":"J. Clin. Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2020.106535_bib0025","first-page":"S39","article-title":"Dravet syndrome: treatment options and management of prolonged seizures","volume":"60","author":"Cross","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0030","first-page":"71","article-title":"Severe myoclonic epilepsy in infancy: Dravet syndrome","volume":"95","author":"Dravet","year":"2005","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0035","series-title":"Epileptic Syndromes in Infancy, Childhood and Adolescence","first-page":"125","article-title":"Dravet syndrome (severe myoclonic epilepsy in infancy)","author":"Dravet","year":"2012"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2014.10.014","article-title":"Efficacy and tolerability of the ketogenic diet in Dravet syndrome \u2013 comparison with various standard antiepileptic drug regimen","volume":"109","author":"Dressler","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0050","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40265-019-01204-y","article-title":"Stiripentol: a review in Dravet syndrome","volume":"79","author":"Frampton","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0055","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0060","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","article-title":"Stiripentol open study in Japanese patients with Dravet syndrome","volume":"50","author":"Inoue","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0065","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","article-title":"Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence","volume":"108","author":"Inoue","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","article-title":"Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy","volume":"130","author":"Jogamoto","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1528-1167.2007.01423.x","article-title":"Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data","volume":"49","author":"Kassai","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0090","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study","volume":"60","author":"Myers","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0095","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1528-1167.2006.00477.x","article-title":"Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan","volume":"47","author":"Oka","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0100","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1528-1167.2011.03053.x","article-title":"Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome","volume":"52","author":"Sakauchi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.yebeh.2014.03.014","article-title":"Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam","volume":"34","author":"Strzelczyk","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.braindev.2008.03.002","article-title":"Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)\u2014a nationwide questionnaire survey in Japan","volume":"30","author":"Tanabe","year":"2008","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0115","first-page":"1120","article-title":"Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet\u2019s syndrome) [in French]","volume":"9","author":"Thanh","year":"2002","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants","volume":"62","author":"Tran","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0125","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/epi.12303","article-title":"Stiripentol in Dravet syndrome: results of a retrospective U.S. study","volume":"54","author":"Wirrell","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0130","doi-asserted-by":"crossref","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","article-title":"Incidence of Dravet syndrome in a US population","volume":"136","author":"Wu","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0387-7604(12)80147-1","article-title":"Early diagnosis of severe myoclonic epilepsy in infancy","volume":"14","author":"Yakoub","year":"1992","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2020.106535_bib0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0883073818811538","article-title":"Efficacy of stiripentol and the clinical outcome in Dravet syndrome","volume":"34","author":"Yildiz","year":"2019","journal-title":"J. Child Neurol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120305866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120305866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:44:09Z","timestamp":1760276649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121120305866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":28,"alternative-id":["S0920121120305866"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106535","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106535"}}